{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:29:50Z","timestamp":1792178990482,"version":"4.4.0"},"reference-count":128,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>This review provides an overview of the management and treatment landscape of inclusion body myositis (IBM), while highlighting the current challenges and future directions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>IBM is a slowly progressive myopathy that predominantly affects patients over the age of 40, leading to increased morbidity and mortality. Unfortunately, a definitive cure for IBM remains elusive. Various clinical trials targeting inflammatory and some of the noninflammatory pathways have failed. The search for effective disease-modifying treatments faces numerous hurdles including variability in presentation, diagnostic challenges, poor understanding of pathogenesis, scarcity of disease models, a lack of validated outcome measures, and challenges related to clinical trial design. Close monitoring of swallowing and respiratory function, adapting an exercise routine, and addressing mobility issues are the mainstay of management at this time.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Addressing the obstacles encountered by patients with IBM and the medical community presents a multitude of challenges. Effectively surmounting these hurdles requires embracing cutting-edge research strategies aimed at enhancing the management and treatment of IBM, while elevating the quality of life for those affected.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000958","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T16:24:52Z","timestamp":1690561492000},"page":"404-413","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["Exploring challenges in the management and treatment of inclusion body myositis"],"prefix":"10.1097","volume":"35","author":[{"given":"Michael P.","family":"Skolka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Naddaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,7,25]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3233\/JND-160198","article-title":"A Systematic review and meta-analysis of prevalence studies of sporadic inclusion body myositis","volume":"4","author":"Callan","year":"2017","journal-title":"J Neuromuscul Dis"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1212\/WNL.28.1.8","article-title":"Inclusion body myositis: a distinct variety of idiopathic inflammatory myopathy","volume":"28","author":"Carpenter","year":"1978","journal-title":"Neurology"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1093\/rheumatology\/keab716","article-title":"Survival and associated comorbidities in inclusion body myositis","volume":"61","author":"Naddaf","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/BOR.0000000000000430","article-title":"Recent clinical trials in idiopathic inflammatory myopathies","volume":"29","author":"Leclair","year":"2017","journal-title":"Curr Opin Rheumatol"},{"issue":"(Pt 3)","key":"R5-20250526","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/brain\/112.3.727","article-title":"Inclusion body myositis. Observations in 40 patients","volume":"112","author":"Lotz","year":"1989","journal-title":"Brain"},{"key":"R6-20250526","first-page":"1385","article-title":"Inclusion body myositis: analysis of 32 cases","volume":"19","author":"Sayers","year":"1992","journal-title":"J Rheumatol"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1007\/s00415-005-0884-y","article-title":"Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients","volume":"252","author":"Badrising","year":"2005","journal-title":"J Neurol"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s13311-018-0658-8","article-title":"Inclusion body myositis: update on pathogenesis and treatment","volume":"15","author":"Naddaf","year":"2018","journal-title":"Neurother"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/mus.27716","article-title":"Atypical presentations of inclusion body myositis: clinical characteristics and long-term outcomes","volume":"66","author":"Alamr","year":"2022","journal-title":"Muscle Nerve"},{"key":"R10-20250526","first-page":"340","article-title":"Two emerging phenotypes of atypical inclusion body myositis: illustrative cases","volume":"41","author":"Salam","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1474-4422(07)70171-0","article-title":"Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches","volume":"6","author":"Needham","year":"2007","journal-title":"Lancet neurol"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/(SICI)1097-4598(200006)23:6<970::AID-MUS20>3.0.CO;2-I","article-title":"Prevalence of sporadic inclusion body myositis in Western Australia","volume":"23","author":"Phillips","year":"2000","journal-title":"Muscle Nerve"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/art.1780300406","article-title":"Inclusion body myositis presenting as treatment-resistant polymyositis","volume":"30","author":"Calabrese","year":"1987","journal-title":"Arthritis Rheum"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","article-title":"Polymyositis, dermatomyositis and inclusion-body myositis","volume":"325","author":"Dalakas","year":"1991","journal-title":"N Engl J Med"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0889-857X(02)00021-2","article-title":"Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria","volume":"28","author":"Mastaglia","year":"2002","journal-title":"Rheum Dis Clin North Am"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/00002281-200211000-00004","article-title":"Inclusion body myositis","volume":"14","author":"Tawil","year":"2002","journal-title":"Curr Opin Rheumatol"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.410380504","article-title":"Inclusion body myositis and myopathies","volume":"38","author":"Griggs","year":"1995","journal-title":"Ann Neurol"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.nmd.2009.11.003","article-title":"MRC centre for neuromuscular diseases, IBM workshop, London, 13 June 2008","volume":"20","author":"Hilton-Jones","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.nmd.2010.03.014","article-title":"International workshop on inclusion body myositis held at the institute of myology, Paris, on 29 May 2009","volume":"20","author":"Benveniste","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.nmd.2013.08.007","article-title":"188th ENMC international workshop: inclusion body myositis, 2\u20134 December 2011, Naarden, The Netherlands","volume":"23","author":"Rose","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"R21-20250526","first-page":"81","article-title":"Inclusion body myositis","author":"Verschuuren","year":"1997","journal-title":"Diagnostic Criteria for Neuromuscular Disorders"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1212\/WNL.55.9.1385","article-title":"Epidemiology of inclusion body myositis in the Netherlands: a nationwide study","volume":"55","author":"Badrising","year":"2000","journal-title":"Neurology"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1212\/WNL.0000000000000642","article-title":"Evaluation and construction of diagnostic criteria for inclusion body myositis","volume":"83","author":"Lloyd","year":"2014","journal-title":"Neurology"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"1020113","DOI":"10.3389\/fneur.2022.1020113","article-title":"Inclusion body myositis: update on the diagnostic and therapeutic landscape","volume":"13","author":"Naddaf","year":"2022","journal-title":"Front Neurol"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.nmd.2019.12.001","article-title":"Myopathies presenting with head drop: clinical spectrum and treatment outcomes","volume":"30","author":"Alhammad","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3109\/02688697.2013.793288","article-title":"Muscle and nerve biopsy for the neurosurgical trainee","volume":"27","author":"Hart","year":"2013","journal-title":"Br J Neurosurg"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.bbadis.2014.08.007","article-title":"Hereditary inclusion-body myopathies","volume":"1852","author":"Broccolini","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.nmd.2010.12.007","article-title":"Myofibrillar myopathies","volume":"21","author":"Selcen","year":"2011","journal-title":"Neuromuscul Disord"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1093\/rheumatology\/keab754","article-title":"Inclusion body myositis: correlation of clinical outcomes with histopathology, electromyography and laboratory findings","volume":"61","author":"Pinto","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s11910-012-0321-4","article-title":"Inclusion body myositis","volume":"13","author":"Dimachkie","year":"2013","journal-title":"Curr Neurol Neurosci Rep"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/mus.24661","article-title":"Magnetic resonance imaging pattern recognition in sporadic inclusion-body myositis","volume":"52","author":"Tasca","year":"2015","journal-title":"Muscle Nerve"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"1146015","DOI":"10.3389\/fneur.2023.1146015","article-title":"Imaging biomarkers in the idiopathic inflammatory myopathies","volume":"14","author":"Zubair","year":"2023","journal-title":"Front Neurol"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11926-020-00947-y","article-title":"Diagnostic value of muscle ultrasound for myopathies and myositis","volume":"22","author":"Albayda","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ana.23822","article-title":"Autoantibodies to cytosolic 5\u2019-nucleotidase 1A in inclusion body myositis","volume":"73","author":"Pluk","year":"2013","journal-title":"Ann Neurol"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.23840","article-title":"Cytosolic 5\u2019-nucleotidase 1A autoimmunity in sporadic inclusion body myositis","volume":"73","author":"Larman","year":"2013","journal-title":"Ann Neurol"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/acn3.51294","article-title":"Clinical utility of anticytosolic 5\u2019-nucleotidase 1A antibody in idiopathic inflammatory myopathies","volume":"8","author":"Ikenaga","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/annrheumdis-2014-206691","article-title":"Disease specificity of autoantibodies to cytosolic 5\u2019-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases","volume":"75","author":"Herbert","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3389\/fimmu.2019.00745","article-title":"Anti-NT5c1A autoantibodies as biomarkers in inclusion body myositis","volume":"10","author":"Amlani","year":"2019","journal-title":"Front Immunol"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1212\/WNL.0000000000200188","article-title":"Inclusion body myositis: autoimmune or myodegenerative disease?","volume":"98","author":"Mammen","year":"2022","journal-title":"Neurology"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"414","DOI":"10.55563\/clinexprheumatol\/pp0oso","article-title":"The role of protein aggregation in the pathogenesis of inclusion body myositis","volume":"40","author":"Snedden","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/BOR.0b013e3282efdc7c","article-title":"Inclusion-body myositis, a multifactorial muscle disease associated with aging: current concepts of pathogenesis","volume":"19","author":"Askanas","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41584-019-0186-x","article-title":"Inclusion body myositis: clinical features and pathogenesis","volume":"15","author":"Greenberg","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"(Pt 5)","key":"R43-20250526","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1093\/brain\/awh148","article-title":"Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity","volume":"127","author":"Schmidt","year":"2004","journal-title":"Brain"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1093\/brain\/awz207","article-title":"Highly differentiated cytotoxic T cells in inclusion body myositis","volume":"142","author":"Greenberg","year":"2019","journal-title":"Brain"},{"issue":"(Suppl 1)","key":"R45-20250526","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1136\/annrheumdis-2022-eular.2141","article-title":"Depletion of klrg1+ T cells in a first-in-human clinical trial of ABC008 in inclusion body myositis (IBM)","volume":"81","author":"Goel","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/hmg\/ddm037","article-title":"Transgenic expression of inclusion body myopathy associated mutant p97\/VCP causes weakness and ubiquitinated protein inclusions in mice","volume":"16","author":"Weihl","year":"2007","journal-title":"Hum Mol Genet"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/mus.23522","article-title":"A progressive translational mouse model of human valosin-containing protein disease: the VCP(R155H\/+) mouse","volume":"47","author":"Nalbandian","year":"2013","journal-title":"Muscle Nerve"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"6334","DOI":"10.1073\/pnas.082545599","article-title":"Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle","volume":"99","author":"Sugarman","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s12035-008-8041-0","article-title":"Inclusion body myositis: a view from the caenorhabditis elegans muscle","volume":"38","author":"Rebolledo","year":"2008","journal-title":"Mol Neurobiol"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"R829","DOI":"10.1152\/ajpregu.00639.2007","article-title":"Rabbits fed cholesterol-enriched diets exhibit pathological features of inclusion body myositis","volume":"294","author":"Chen","year":"2008","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"eabi9196","DOI":"10.1126\/scitranslmed.abi9196","article-title":"Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis","volume":"14","author":"Britson","year":"2022","journal-title":"Sci Transl Med"},{"key":"R52-20250526","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2353\/ajpath.2009.080422","article-title":"Role of regulatory T cells in a new mouse model of experimental autoimmune myositis","volume":"174","author":"Allenbach","year":"2009","journal-title":"Am J Pathol"},{"key":"R53-20250526","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11926-012-0245-7","article-title":"Animal models of inflammatory myopathy","volume":"14","author":"Ascherman","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"R54-20250526","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1128\/JVI.02799-06","article-title":"Complement contributes to inflammatory tissue destruction in a mouse model of Ross River virus-induced disease","volume":"81","author":"Morrison","year":"2007","journal-title":"J Virol"},{"key":"R55-20250526","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.virol.2007.10.020","article-title":"Interactions between multiple genetic determinants in the 5\u2019 UTR and VP1 capsid control pathogenesis of chronic postviral myopathy caused by coxsackievirus B1","volume":"372","author":"Sandager","year":"2008","journal-title":"Virology"},{"key":"R56-20250526","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.4049\/jimmunol.179.6.3772","article-title":"Attenuation of experimental autoimmune myositis by blocking ICOS-ICOS ligand interaction","volume":"179","author":"Katsumata","year":"2007","journal-title":"J Immunol"},{"key":"R57-20250526","doi-asserted-by":"crossref","first-page":"e2653","DOI":"10.1212\/WNL.0000000000012004","article-title":"Epidemiology and natural history of inclusion body myositis: a 40-year population-based study","volume":"96","author":"Shelly","year":"2021","journal-title":"Neurology"},{"issue":"(Pt 11)","key":"R58-20250526","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1093\/brain\/awr217","article-title":"A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities","volume":"134","author":"Cox","year":"2011","journal-title":"Brain"},{"key":"R59-20250526","first-page":"13","article-title":"Longitudinal observational study investigating outcome measures for clinical trials in inclusion body myositis","volume":"13","author":"Sangha","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R60-20250526","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/BOR.0000000000000327","article-title":"Epidemiology of sporadic inclusion body myositis","volume":"28","author":"Molberg","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"R61-20250526","first-page":"1","article-title":"Diagnosing and managing dysphagia in inclusion body myositis: a systematic review","volume":"00","author":"Ambrocio","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"R62-20250526","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/hed.24400","article-title":"Outcomes of endoscopic cricopharyngeal myotomy with CO2 laser surgery: a retrospective study of 47 patients","volume":"38","author":"Hoesseini","year":"2016","journal-title":"Head Neck"},{"key":"R63-20250526","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4137\/CCRep.S10200","article-title":"Balloon dilation in sporadic inclusion body myositis patients with Dysphagia","volume":"6","author":"Murata","year":"2013","journal-title":"Clin Med Insights Case Rep"},{"key":"R64-20250526","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1007\/s00415-022-11028-8","article-title":"Botulinum toxin treatment improves dysphagia in patients with oculopharyngeal muscular dystrophy and sporadic inclusion body myositis","volume":"269","author":"Witting","year":"2022","journal-title":"J Neurol"},{"key":"R65-20250526","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","article-title":"Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study","volume":"48","author":"Dalakas","year":"1997","journal-title":"Neurology"},{"key":"R66-20250526","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s004150050005","article-title":"High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study","volume":"247","author":"Walter","year":"2000","journal-title":"J Neurol"},{"key":"R67-20250526","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00005792-199307000-00002","article-title":"The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy","volume":"72","author":"Leff","year":"1993","journal-title":"Medicine (Baltimore)"},{"key":"R68-20250526","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1212\/WNL.56.3.323","article-title":"A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM","volume":"56","author":"Dalakas","year":"2001","journal-title":"Neurology"},{"key":"R69-20250526","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/ana.10121","article-title":"Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo","volume":"51","author":"Badrising","year":"2002","journal-title":"Ann Neurol"},{"key":"R70-20250526","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1212\/01.WNL.0000134675.98525.79","article-title":"Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis","volume":"63","author":"Muscle Study","year":"2004","journal-title":"Neurology"},{"key":"R71-20250526","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/ard.2007.077974","article-title":"A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies","volume":"67","author":"Dastmalchi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R72-20250526","first-page":"887","article-title":"Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy","volume":"26","author":"Sultan","year":"2008","journal-title":"Clin Exp Rheumatol"},{"issue":"(1\u20132)","key":"R73-20250526","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jns.2013.08.007","article-title":"The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study","volume":"334","author":"Kosmidis","year":"2013","journal-title":"J Neurol Sci"},{"issue":"(Suppl. 1)","key":"R74-20250526","article-title":"Interim analysis of a pilot trial of natalizumab in inclusion body myositis","volume":"86","author":"Saperstein","year":"2016","journal-title":"Neurology Conference: 68th American Academy of Neurology Annual Meeting, AAN"},{"key":"R75-20250526","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12883-016-0568-5","article-title":"Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM","volume":"16","author":"Schmidt","year":"2016","journal-title":"BMC Neurol"},{"key":"R76-20250526","doi-asserted-by":"crossref","first-page":"e581","DOI":"10.1212\/NXI.0000000000000581","article-title":"Trial of canakinumab, an IL-1beta receptor antagonist, in patients with inclusion body myositis","volume":"6","author":"Kosmidis","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"(Suppl 1)","key":"R77-20250526","first-page":"S123","article-title":"Pilot trial of etanercept in the treatment of inclusion-body myositis","volume":"66","author":"Barohn","year":"2006","journal-title":"Neurology"},{"key":"R78-20250526","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1212\/WNL.58.7.1081","article-title":"A pilot randomized trial of oxandrolone in inclusion body myositis","volume":"58","author":"Rutkove","year":"2002","journal-title":"Neurology"},{"key":"R79-20250526","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s10072-011-0657-6","article-title":"Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis","volume":"32","author":"Sancricca","year":"2011","journal-title":"Neurol Sci"},{"key":"R80-20250526","first-page":"e1416","article-title":"Immunoregulatory effects of testosterone supplementation combined with exercise training in men with inclusion body myositis: a double-blind, placebo-controlled, cross-over trial","volume":"11","author":"Coudert","year":"2022","journal-title":"Clin"},{"key":"R81-20250526","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/S2665-9913(20)30280-0","article-title":"Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial","volume":"3","author":"Benveniste","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"(19)","key":"R82-20250526","first-page":"S102","article-title":"A pilot study of triheptanoin treatment in sporadic inclusion body myositis (SIBM)","author":"Corbett","year":"2015","journal-title":"Ann Neurol"},{"key":"R83-20250526","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.ymthe.2017.02.015","article-title":"Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes","volume":"25","author":"Mendell","year":"2017","journal-title":"Mol Ther"},{"key":"R84-20250526","doi-asserted-by":"crossref","first-page":"e1595","DOI":"10.1212\/WNL.0000000000011626","article-title":"Efficacy and safety of bimagrumab in sporadic inclusion body myositis: long-term extension of RESILIENT","volume":"96","author":"Amato","year":"2021","journal-title":"Neurology"},{"issue":"(Suppl)","key":"R85-20250526","first-page":"S8","article-title":"Phase 2\/3 study of arimoclomol in IBM","volume":"23","author":"Machado","year":"2022","journal-title":"J"},{"key":"R86-20250526","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/sms.14079","article-title":"Effects of blood-flow restricted resistance training on mechanical muscle function and thigh lean mass in sIBM patients","volume":"32","author":"Jorgensen","year":"2022","journal-title":"Scand J Med Sci Sports"},{"issue":"(Suppl 1)","key":"R87-20250526","first-page":"S5","article-title":"Evaluating the benefits of community based aerobic training on the physical health and well being of people with neuromuscular disease","volume":"54","author":"Wallace","year":"2016","journal-title":"Muscle and Nerve"},{"key":"R88-20250526","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/16501970306110","article-title":"Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction","volume":"35","author":"Arnardottir","year":"2003","journal-title":"J Rehabil Med"},{"key":"R89-20250526","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s13023-021-01928-9","article-title":"Cybernic treatment with wearable cyborg Hybrid Assistive Limb (HAL) improves ambulatory function in patients with slowly progressive rare neuromuscular diseases: a multicentre, randomised, controlled crossover trial for efficacy and safety (NCY-3001)","volume":"16","author":"Nakajima","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"R90-20250526","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/0309364610389352","article-title":"Stance control orthosis trial in patients with inclusion body myositis","volume":"35","author":"Bernhardt","year":"2011","journal-title":"Prosthet Orthot Int"},{"key":"R91-20250526","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.nmd.2020.02.010","article-title":"Exploring the efficacy of the expiratory muscle strength trainer to improve swallowing in inclusion body myositis: a pilot study","volume":"30","author":"Mohannak","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"R92-20250526","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-015-0314-4","article-title":"Effectiveness and cost-effectiveness of a self-management group program to improve social participation in patients with neuromuscular disease and chronic fatigue: protocol of the Energetic study","volume":"15","author":"Veenhuizen","year":"2015","journal-title":"BMC Neurol"},{"key":"R93-20250526","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1212\/WNL.0000000000000588","article-title":"Shared medical appointments improve QOL in neuromuscular patients: a randomized controlled trial","volume":"83","author":"Seesing","year":"2014","journal-title":"Neurology"},{"key":"R94-20250526","first-page":"370","article-title":"Current status of clinical outcome measures in inclusion body myositis: a systematised review","volume":"41","author":"Roy","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"R95-20250526","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.chest.2019.10.014","article-title":"Six-minute walk test: clinical role, technique, coding, and reimbursement","volume":"157","author":"Agarwala","year":"2020","journal-title":"Chest"},{"key":"R96-20250526","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ncl.2014.04.001","article-title":"Inclusion body myositis","volume":"32","author":"Dimachkie","year":"2014","journal-title":"Neurol Clin"},{"key":"R97-20250526","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.nmd.2022.08.005","article-title":"Correlations of disease severity outcome measures in inclusion body myositis","volume":"32","author":"Goyal","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"R98-20250526","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/mus.20958","article-title":"Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity","volume":"37","author":"Jackson","year":"2008","journal-title":"Muscle Nerve"},{"key":"R99-20250526","doi-asserted-by":"crossref","first-page":"e200168","DOI":"10.1212\/CPJ.0000000000200168","article-title":"Study to assess content validity and interrater and intrarater reliability of the inclusion body myositis functional rating scale","volume":"13","author":"Symonds","year":"2023","journal-title":"Neurol Clin Pract"},{"key":"R100-20250526","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-4-79","article-title":"Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance","volume":"4","author":"Health USDo","year":"2006","journal-title":"Health Qual Life Outcomes"},{"key":"R101-20250526","doi-asserted-by":"crossref","first-page":"e865","DOI":"10.1212\/WNL.0000000000200776","article-title":"Longitudinal changes in MRI muscle morphometry and composition in people with inclusion body myositis","volume":"99","author":"Laurent","year":"2022","journal-title":"Neurology"},{"key":"R102-20250526","first-page":"A332","article-title":"High-dose intravenous immunoglobulin (IVIg) combined with Prednisone in the treatment of patients with inclusion-body myositis (IBM): a double-blind, randomised controlled trial","volume":"48","author":"Dalakas","year":"1997","journal-title":"Neurology"},{"key":"R103-20250526","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1212\/WNL.0000000000001070","article-title":"Treatment of sporadic inclusion body myositis with bimagrumab","volume":"83","author":"Amato","year":"2014","journal-title":"Neurology"},{"key":"R104-20250526","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMra1510059","article-title":"Pragmatic trials","volume":"375","author":"Ford","year":"2016","journal-title":"N Engl J Med"},{"key":"R105-20250526","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2217\/pme.11.7","article-title":"The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?","volume":"8","author":"Lillie","year":"2011","journal-title":"Per Med"},{"key":"R106-20250526","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13073-022-01102-1","article-title":"Clinical trial design in the era of precision medicine","volume":"14","author":"Fountzilas","year":"2022","journal-title":"Genome Med"},{"key":"R107-20250526","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/jnnp.2009.190751","article-title":"Distal muscle involvement in granulomatous myositis can mimic inclusion body myositis","volume":"82","author":"Larue","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R108-20250526","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.clineuro.2019.05.001","article-title":"Chronic sarcoid myopathy mimicking sporadic inclusion body myositis","volume":"182","author":"Miyazaki","year":"2019","journal-title":"Clin Neurol Neurosurg"},{"key":"R109-20250526","doi-asserted-by":"crossref","first-page":"e2212","DOI":"10.1212\/WNL.0000000000201103","article-title":"Morphologic and molecular patterns of polymyositis with mitochondrial pathology and inclusion body myositis","volume":"99","author":"Kleefeld","year":"2022","journal-title":"Neurology"},{"key":"R110-20250526","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/mus.10528","article-title":"Amyloid myopathy presenting with distal atrophic weakness","volume":"29","author":"Smestad","year":"2004","journal-title":"Muscle Nerve"},{"key":"R111-20250526","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00415-014-7570-x","article-title":"Natural history of skeletal muscle involvement in myotonic dystrophy type 1: a retrospective study in 204 cases","volume":"262","author":"Bouchard","year":"2015","journal-title":"J Neurol"},{"key":"R112-20250526","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/ene.15174","article-title":"Muscle magnetic resonance imaging in myotonic dystrophy type 1 (DM1): Refining muscle involvement and implications for clinical trials","volume":"29","author":"Garibaldi","year":"2022","journal-title":"Eur J Neurol"},{"key":"R113-20250526","doi-asserted-by":"crossref","first-page":"e2803","DOI":"10.1212\/WNL.0000000000007648","article-title":"Lower extremity muscle pathology in myotonic dystrophy type 1 assessed by quantitative MRI","volume":"92","author":"Heskamp","year":"2019","journal-title":"Neurology"},{"key":"R114-20250526","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1212\/01.WNL.0000054481.84978.F9","article-title":"Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum","volume":"60","author":"Day","year":"2003","journal-title":"Neurology"},{"key":"R115-20250526","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jns.2015.11.009","article-title":"Dysferlinopathy in Iran: clinical and genetic report","volume":"359","author":"Fatehi","year":"2015","journal-title":"J Neurol Sci"},{"key":"R116-20250526","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1136\/jnnp-2017-317488","article-title":"Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials","volume":"89","author":"Diaz-Manera","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R117-20250526","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/mus.24773","article-title":"Late-onset Becker muscular dystrophy: refining the clinical features and electrophysiological findings","volume":"52","author":"Beltran Papsdorf","year":"2015","journal-title":"Muscle Nerve"},{"key":"R118-20250526","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ajhg.2011.04.021","article-title":"Mutations in the N-terminal actin-binding domain of filamin C cause a distal myopathy","volume":"88","author":"Duff","year":"2011","journal-title":"Am J Hum Genet"},{"key":"R119-20250526","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1007\/s00415-019-09437-3","article-title":"HNRNPDL-related muscular dystrophy: expanding the clinical, morphological and MRI phenotypes","volume":"266","author":"Berardo","year":"2019","journal-title":"J Neurol"},{"key":"R120-20250526","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.nmd.2012.09.009","article-title":"Novel valosin containing protein mutation in a Swiss family with hereditary inclusion body myopathy and dementia","volume":"23","author":"Peyer","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"R121-20250526","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/ejhg.2015.78","article-title":"Genetics of GNE myopathy in the non-Jewish Persian population","volume":"24","author":"Haghighi","year":"2016","journal-title":"Eur J Hum Genet"},{"key":"R122-20250526","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.nmd.2010.01.012","article-title":"The p.G154S mutation of the alpha-B crystallin gene (CRYAB) causes late-onset distal myopathy","volume":"20","author":"Reilich","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"R123-20250526","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.nmd.2006.04.009","article-title":"Myotilinopathy in a family with late onset myopathy","volume":"16","author":"Penisson-Besnier","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"R124-20250526","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/acn3.140","article-title":"Laing distal myopathy pathologically resembling inclusion body myositis","volume":"1","author":"Roda","year":"2014","journal-title":"Ann Clin Transl Neurol"},{"key":"R125-20250526","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/mus.24674","article-title":"Novel presentation of Pompe disease: inclusion-body myositis-like clinical phenotype","volume":"52","author":"Bandyopadhyay","year":"2015","journal-title":"Muscle Nerve"},{"key":"R126-20250526","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/mus.26914","article-title":"Myopathies with finger flexor weakness: not only inclusion-body myositis","volume":"62","author":"Nicolau","year":"2020","journal-title":"Muscle Nerve"},{"key":"R127-20250526","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.nmd.2019.02.012","article-title":"ACTA1-myopathy with prominent finger flexor weakness and rimmed vacuoles","volume":"29","author":"Liewluck","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"R128-20250526","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1212\/01.WNL.0000071852.27182.C7","article-title":"Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study","volume":"61","author":"Lindberg","year":"2003","journal-title":"Neurology"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000958","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:21:28Z","timestamp":1748294488000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,25]]},"references-count":128,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000958","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,25]]}}}